What we DON’T know from the ASCO abstracts …

Near the end of last month we had told you that data from the LATITUDE trial and from Arm G of the STAMPEDE trial would be presented at the ASCO annual meeting in Chicago this year. … READ MORE …

Unwarranted conclusions about treatment of oligometastatic prostate cancer

Many patients wonder, if they just have a couple of metastases, why can’t those be “zapped” by a few quick SBRT treatments and they can’t thereby be cured of their prostate cancer? Or, even if they can’t be cured, can’t the cancer’s progression be slowed down? … READ MORE …

An update to the PrEvENT trial in England

The Prostate Cancer: Evidence of Exercise and Nutrition Trial (PrEvENT) has been ongoing in England since August 2014 and is an important and serious exploration of how diet and exercise may affect the outcomes of men who are treated for prostate cancer. … READ MORE …

Data from the LATITUDE trial to be presented at ASCO

According to an e-mail your sitemaster has just received from ASCO, we will be getting the initial results from the LATITUDE trial at the upcoming ASCO meeting in June this year. … READ MORE …

Aggressive, trimodal therapy active in treatment of selected men with M1 prostate cancer

A new report in the journal Urology has shown that a subset of men with metastatic disease can be placed in long-term remission through the use of a combination of androgen deprivation therapy (ADT) + surgery + radiation therapy. … READ MORE …

Active surveillance in men with higher-risk forms of localized prostate cancer

The abstract of a paper currently in press in the Journal of Urology has offered us some potentially fascinating insight into the comparative outcomes of patients with low- and higher-risk forms of localized prostate cancer when they are initially managed on active surveillance. … READ MORE …

15-year metastasis-free survival in men on active surveillance in The Netherlands

According to new data reported at the annual meeting of the European Association of Urology in London, active surveillance of men diagnosed with low-risk prostate cancer was not associated with an elevated risk for metastatic disease at 15 years of follow-up. … READ MORE …